Download PDF
Thromb Haemost 1986; 55(02): 228-234
DOI: 10.1055/s-0038-1661527
Original Article
Schattauer GmbH Stuttgart

Modification of Platelet Functions by Monobromobimane, a Fluorescent Thiol Group Label

Marjorie B Zucker
The Department of Pathology New York University Medical Center, New York, NY, USA
,
Evelyn A Mauss
The Department of Pathology New York University Medical Center, New York, NY, USA
› Author Affiliations
Further Information

Publication History

Received 04 October 1985

Accepted 06 February 1986

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Monobromobimane (mBBr, bimane), a compound that penetrates cells and forms a fluorescent adduct with thiol groups, was used to assess the significance of thiols in platelet function. Exposure of washed platelets for 1 min to 100 μM mBBr abolished ADP-induced aggregation; shape change was not inhibited by 500 μM mBBr. The nonpenetrating compound monobromotrimethylammoniobimane was ineffective. Established ADP-induced aggregation was reversed by bimane, and fibrinogen binding to ADP-stimulated platelets was inhibited, an effect mainly due to decreased number of binding sites. Aggregation stimulated by A23187 and arachidonate was less effectively inhibited whereas epinephrine- and collagen-induced aggregation were abolished by 50 μM mBBr. Similar effects on aggregation and secretion were observed in platelet-rich plasma except that higher mBBr concentrations were usually necessary. Aggregation and 14C-serotonin secretion stimulated by 0.1 U/ml thrombin were partially inhibited by pretreatment with bimane. With lower thrombin concentrations, they were often enhanced, as was 3H-arachidonate release. Bimane inhibited epinephrine-induced arachidonate release in gel-filtered platelets, possibly because it abolished the primary aggregation necessary for this release. mBBr did not elevate cyclic AMP but enhanced the increase induced by PGEi and prevented the subsequent decrease typically caused by ADP. Examination of SDS polyacrylamide gels with ultraviolet light showed that mBBr reacted with many platelet proteins but not with GP lib or Ilia. This observation, and the fact that bimane did not inhibit the fibrinogen-induced aggregation of DTT- or chymotrypsin-treated platelets suggest that it reacts with thiol group(s) that are involved in “exposing” the fibrinogen receptor.

Key words

Platelets - Bimane - Thiol group label
 

  • References

  • 1 Aledort LM, Troup SB, Weed RI. Inhibition of sulfhydryl-dependent platelet functions by penetrating and non-penetrating analogues of parachloromercuribenzene. Blood 1968; 31: 471-479
    PubMedGoogle Scholar
  • 2 Harbury CB, Schrier SL. Modification of platelet sulfhydryl groups. Thrombos Diathes Haemorrh 1974; 31: 469-484
    PubMedGoogle Scholar
  • 3 MacIntyre DE, Grainge CA, Drummond AH, Gordon JL. Effect of thio reagents on platelet transport processes and responses to stimuli. Biochem Pharmacol 1977; 26: 319-323
    CrossrefPubMedGoogle Scholar
  • 4 MacIntyre DE, Gordon JL. Evidence for two populations of disulphide bonds on blood platelets. Biochem Soc Trans 1974; 2: 873-875
    CrossrefPubMedGoogle Scholar
  • 5 Zucker MB, Masiello NC. Platelet aggregation caused by dithio-threitol. Thromb Haemostas 1984; 51: 119-124
    PubMedGoogle Scholar
  • 6 Kosower EM, Correa W, Kinon BJ, Kosower NS. Glutathione VII. Differentiation among substrates by the thiol-oxidizing agent, diamide. Biochim Biophys Acta 1972; 264: 39-44
    PubMedGoogle Scholar
  • 7 Bosia A, Spangenberg P, Losche W, Arese P, Till U. The role of the GSH-disulfide status in the reversible and irreversible aggregation of human platelets. Thromb Res 1983; 30: 137-142
    CrossrefPubMedGoogle Scholar
  • 8 Patscheke H, Worner P. Sequential effects of the thiol-oxidizing agent, diamide, on human platelets. Thromb Res 1978; 12: 609-618
    CrossrefPubMedGoogle Scholar
  • 9 Kosower NS, Kosower EM, Newton GL, Ranney HM. Bimane fluorescent labels: Labeling of normal human red cells under physiological conditions. Proc Natl Acad Sci 1979; 76: 3382-3386
    CrossrefPubMedGoogle Scholar
  • 10 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204
    CrossrefPubMedGoogle Scholar
  • 11 Zucker MB, Masiello NC. The Triton-X-100-insoluble residue (“cytoskeleton”) of aggregated platelets contains increased lipid phosphorous as well as 125I-labeled glycoproteins. Blood 1983; 61: 676-683
    PubMedGoogle Scholar
  • 12 Phillips DR, Agin PP. Platelet and plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced - reduced two-dimensional gel electrophoresis. J Biol Chem 1977; 252: 2121-2126
    PubMedGoogle Scholar
  • 13 Greenberg JP, Packham MA, Guccione MA, Harfenist EJ, Orr JL, Kinlough-Rathbone RL, Perry DW, Mustard JF. The effect of pretreatment of human or rabbit platelets with chymotrypsin on their responses to human fibrinogen and aggregating agents. Blood 1979; 54: 753-765
    PubMedGoogle Scholar
  • 14 Niewiarowski S, Budzynski AZ, Morinelli TA, Brudzynski TM, Stewart GJ. Exposure of fibrinogen receptor on human platelets by proteolytic enzymes. J Biol Chem 1981; 256: 917-925
    PubMedGoogle Scholar
  • 15 Holme S, Murphy S. Quantitative measurements of platelet shape by light transmission studies; application to storage of platelets for transfusion. J Lab Clin Med 1978; 92: 53-64
    PubMedGoogle Scholar
  • 16 Valdorf-Hansen JF, Zucker MB. Effect of temperature and inhibitors on serotonin-C14 release from human platelets. Am J Physiol 1971; 220: 105-111
    PubMedGoogle Scholar
  • 17 Packham MA, Guccione MA, Greenberg JP, Kinlough-Rathbone RL, Mustard JF. Release of 14C-serotonin during initial platelet changes induced by thrombin, collagen, or A23187. Blood 1977; 50: 915-926
    PubMedGoogle Scholar
  • 18 Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55: 841-847
    PubMedGoogle Scholar
  • 19 Marcus AJ. Platelet arachidonic acid metabolism. In: Measurement of Platelet Function Harker LA, Zimmerman TS. (eds) Churchill Livingstone; New York: 1983: 126-143
  • 20 Connolly TM, Limbird LE. The influence of Na+ on the 2-adrenergic receptor system of human platelets. J Biol Chem 1983; 258: 3907-3912
    PubMedGoogle Scholar
  • 21 Jennings LK, Phillips DR. Purification of glycoproteins lib and Ilia from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb—III complex. J Biol Chem 1982; 257: 10458-10466
    PubMedGoogle Scholar
  • 22 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 23 Haslam RJ, Davidson M ML, Davies T, Lynham JA, McCleneghan MD. Regulation of blood platelet function by cyclic nucleotides. In: Advances in Cyclic Nucleotide Research George WJ, Ignarro LJ. (eds) Raven Press; New York: 1978: 533-552
  • 24 Simpson RB, Saroff HA. Decrease in sulfhydryl titer of serum albumin. JACS 1958; 80: 2129-2131
    CrossrefPubMedGoogle Scholar
  • 25 Peerschke EIB. The platelet fibrinogen receptor. Sem Hematol 1985; 22: 241-259
    PubMedGoogle Scholar
  • 26 Kalomiris EL, Coller BS. Thiol-specific probes indicate that the beta chain of platelet glycoproteins lb is a transmembrane protein with a reactive endofacial sulfhydryl group. Biochemistry 1985; 24: 5430-5436
    CrossrefPubMedGoogle Scholar
  • 27 Peerschke EI, Coller BS. A murine monoclonal antibody that blocks fibrinogen binding to normal platelets also inhibits fibrinogen interactions with chymotrypsin-treated platelets. Blood 1984; 64: 59-63
    PubMedGoogle Scholar
  • 28 Kornecki E, Tuszynski GP, Niewiarowski S. Inhibition of fibrinogen receptor-mediated platelet aggregation by heterologous anti-human platelet membrane antibody. J Biol Chem 1983; 258: 9349-9356
    PubMedGoogle Scholar
  • 29 Peerschke EI, Zucker MB. Fibrinogen receptor exposure and aggregation of human blood platelets produced by ADP and chilling. Blood 1981; 57: 663-670
    PubMedGoogle Scholar
  • 30 Silk ST, Wong K TH, Marcus AJ. Arachidonic acid releasing activity in platelet membranes: Effects of sulfhydryl-modifying reagents. Biochem 1981; 20: 391-397
    CrossrefPubMedGoogle Scholar
  • 31 Sweatt D, Johnson SL, Cragoe EJ, Limbird LE. Inhibitors of sodium-proton (Na+/H+) exchange block stimulus-provoked arachidonic acid release in human platelets. J Biol Chem 1985; 260: 12910-12919
    PubMedGoogle Scholar
  • 32 Ostermann G, Spangenberg P, Meyer M, Hermann FH, Till U. The effect of diamide (azodicarboxylic acid-bis-dimethylamide) on sulfhydryl group content, proteins, and the location of phosphatidyl-ethanolamine in human blood platelets. Acta Haemat 1982; 68: 278-284
    CrossrefPubMedGoogle Scholar
  • 33 Davies GE, Palek J. Platelet protein organization: analysis by treatment with membrane-permeable cross-linking reagents. Blood 1982; 59: 502-513
    PubMedGoogle Scholar
  • 34 Hofmann J, Losche W, Till U, Bosia A, Arese P, Pescarmona C, Thielman K. Effect of decreased GSH level on human platelet functions. Artery 1980; 8: 431-436
    PubMedGoogle Scholar
  • 35 Steen VM, Holmsen H. Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change. Thromb Haemostas 1984; 52: 333-335
    PubMedGoogle Scholar
  • 36 Jakobs KH, Lasch P, Minuth M, Aktories K, Schultz G. Uncoupling of α-adrenoceptor-mediated inhibition of human platelet adenylate cyclase by N-ethylmaleimide. J Biol Chem 1982; 257: 2829-2833
    PubMedGoogle Scholar
  • 37 Macfarlane DE, Mills DC B, Srivastava P. Binding of 2-azido-adenosine (β-32P) diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry 1982; 21: 544-549
    CrossrefPubMedGoogle Scholar
  • 38 Lau BHS, Adetumbi MA, Sanchez A. Allium sativum (garlic) and atherosclerosis: a Review. Nutr Res 1983; 3: 119-128
    CrossrefPubMedGoogle Scholar
  • 39 Block E. The chemistry of garlic and onions. Sci Amer 1985; 252: 114-119
    PubMedGoogle Scholar
  • 40 Apitz-Castro R, Cabrera S, Cruz MR, Ledezma E, Jain MK. Effect of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure. Thromb Res 1983; 32: 155-169
    CrossrefPubMedGoogle Scholar
  • 41 Apitz-Castro R, Ledezma E, Jain MK, Block E. Ajoene: the major antiaggregatory compound derived from garlic specifically inhibits the release reaction and fibrinogen binding. Thromb Haemost 1985; 54: 126 (Abstr)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Ariga T, Susumu O, Tamada T. Platelet aggregation inhibitor in garlic. Lancet 1981; 1: 150-151
    PubMedGoogle Scholar
  • 43 Wills ED. Enzyme inhibition by allicin, the active principle of garlic. Biochem J 1956; 63: 514-520
    CrossrefPubMedGoogle Scholar
  • 44 Yamada K, Shuto K, Nakamizo N. Inhibition of platelet aggregation by a new agent, 2,2’-dithiobis-(N-2-hydroxypropyl benzamide) (KF4939). Thromb Res 1983; 29: 197-206
    CrossrefPubMedGoogle Scholar
  • 45 Yamada K, Kubo K, Shuto K, Nakamizo N. Involvement of disulfide-sulfhydryl interaction in anti-platelet actions of KF4939. Thromb Res 1985; 38: 61-69
    CrossrefPubMedGoogle Scholar
  • 46 Bonne C, Martin B, Regnault F. Hypothetic mechanism of ticlopidine-induced hypersensitivity to PGE1 in rat platelets. Thromb Res 1981; 21: 157-164
    CrossrefPubMedGoogle Scholar
  • 47 DiMinno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-338
    CrossrefPubMedGoogle Scholar